Genprex Inc. (NASDAQ:GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has said its chairman and chief executive officer, Rodney Varner, has participated in a second-round live interview on the ‘Big Biz Show’, an emmy award-winning nationally syndicated TV and radio show.
During the interview Varner discussed Genprex’s lead drug candidate, GPX-001, for non-small cell lung cancer; how the company is forging ahead during the coronavirus (COVID-19) pandemic; company catalysts coming in the next 18 months; and the recent National Institutes of Health $2.59 million research grant awarded to its collaborators at the University of Pittsburgh for its licensed diabetes gene therapy.
READ: Genprex advisor George Gittes wins $2.6 million NIH grant to develop diabetes gene therapy, GPX-002
The ‘Big Biz Show’ covers current business events, internet-related issues and other hot topics in the business world and is seen and heard in over 100 million broadcast TV homes, 150 radio stations in the US and in 175 countries. The emmy award-winning show was named by TALKERS Magazine as one of the “Top 10 Most Influential Financial Shows.”
A replay of the interview is available for viewing on the company’s website at https://bit.ly/2Esvq05.
Varner’s first live appearance on the Big Biz Show in June 2020, visit Genprex’s website: https://www.genprex.com/videos/
Contact the author at firstname.lastname@example.org